- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13:00 | Polyrizon Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 06.11. | Polyrizon: Nasengel zeigt in Labortests Schutzwirkung gegen H1N1-Virus | 1 | Investing.com Deutsch | ||
| 06.11. | Polyrizon's nasal gel shows protection against H1N1 in lab tests | 2 | Investing.com | ||
| 06.11. | Polyrizon Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| POLYRIZON Aktie jetzt für 0€ handeln | |||||
| 06.11. | Polyrizon Ltd.: Polyrizon Demonstrates Reversible Broad-Spectrum Viral Blocking by Its Intranasal Barrier-Forming Formulation | 1 | GlobeNewswire (USA) | ||
| 06.10. | Polyrizon Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 06.10. | Polyrizon Ltd.: Polyrizon Announces Positive Pre-Clinical Results: PL-14 Demonstrates Encouraging Allergen-Blocking Efficacy | 140 | GlobeNewswire (Europe) | Ra'anana, Israel, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) ("Polyrizon" or the "Company"), a biotechnology company developing intranasal products based on its proprietary Capture... ► Artikel lesen | |
| 19.09. | Polyrizon submits FDA pre-submission package for allergy nasal spray | 1 | Investing.com | ||
| 19.09. | Polyrizon Ltd.: Polyrizon Submits Pre-Sub Package to the FDA for PL-14 Allergy Blocker | 1 | GlobeNewswire (USA) | ||
| 17.09. | Polyrizon Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 12.09. | Polyrizon reports positive preclinical results for nasal allergy blocker | 1 | Investing.com | ||
| 12.09. | Polyrizon meldet positive präklinische Ergebnisse für nasalen Allergie-Blocker | 1 | Investing.com Deutsch | ||
| 12.09. | Polyrizon Ltd.: Polyrizon Reports Successful Intranasal Delivery of PL-14 Allergy Blocker in Latest Study | 148 | GlobeNewswire (Europe) | Ra'anana, Israel, Sept. 12, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) ("Polyrizon" or the "Company"), a biotechnology company focusing on the development of intranasal products, today... ► Artikel lesen | |
| 04.09. | Polyrizon Ltd. - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 14.08. | Polyrizon regains compliance with Nasdaq listing requirements | 2 | Investing.com | ||
| 14.08. | Polyrizon Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 14.08. | Polyrizon Ltd.: Polyrizon Regains Compliance with Nasdaq Listing Requirements | 311 | GlobeNewswire (Europe) | Ra'anana, Israel, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) ("Polyrizon" or the "Company"), a biotechnology company focusing on the development of intranasal products, today... ► Artikel lesen | |
| 31.07. | Polyrizon Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 24.07. | Polyrizon Ltd. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 22.07. | Polyrizon Stock Jumps 53% On Positive Preclinical Results For Allergy Blocker | 1 | RTTNews |
1 2 3 Weiter >>
46 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 41,790 | +1,79 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen mit einem Kursziel von 57 US-Dollar auf "Buy" belassen. Die Profitabilität dürfte 2026 zumindest stabil bleiben... ► Artikel lesen | |
| NOVAVAX | 5,811 | +1,06 % | NOVAVAX INC zittert - jetzt entscheidet sich alles! | ||
| 4SC | 0,300 | +20,00 % | PTA-News: 4SC AG: Start der Umsetzung der von der ordentl. HV 2025 beschlossenen Kapitalmaßnahmen vorauss. in der 2. Novemberhälfte 2025 | DJ PTA-News: 4SC AG: Start der Umsetzung der von der ordentl. HV 2025 beschlossenen Kapitalmaßnahmen vorauss. in der 2. Novemberhälfte 2025
Unternehmensmitteilung für den Kapitalmarkt
4SC... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 18,970 | -5,15 % | Palatin Technologies, Inc.: Palatin Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update | Significant progress on multiple fronts - obesity pipeline advancing towards the clinic, out-licensing collaboration, strengthened balance sheet, and reinstatement... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,540 | -1,91 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Third Quarter 2025 Financial Results and Recent Business Highlights | Completed rolling Biologics License Application (BLA) submission seeking accelerated approval for lead candidate INO-3107; requested priority review
Expect... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 1,740 | -0,57 % | COSCIENS Biopharma Inc. Announces Leadership Change | TORONTO, ONTARIO, Nov. 14, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (FINRA: CSCIF) ("COSCIENS" or the "Company"), a life science company focused on natural ingredients and pharmaceutical... ► Artikel lesen | |
| XOMA ROYALTY | 27,400 | -0,72 % | XOMA Royalty Corporation: XOMA Royalty Announces Closing of Transactions to Acquire LAVA Therapeutics N.V. | EMERYVILLE, Calif., Nov. 21, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation ("XOMA Royalty") (Nasdaq: XOMA) today announced it has successfully completed its previously announced acquisition of... ► Artikel lesen | |
| PHIO PHARMACEUTICALS | 1,200 | +2,13 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Completion of Enrollment in Phase 1b Clinical Trial of INTASYL siRNA Lead Compound PH-762 | King of Prussia, Pennsylvania--(Newsfile Corp. - November 25, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its... ► Artikel lesen | |
| MOSAIC IMMUNOENGINEERING | - | - | Mosaic ImmunoEngineering Inc. - 10-Q, Quarterly Report | ||
| T2 BIOSYSTEMS | 0,250 | 0,00 % | NSE/A - T2 Biosystems, Inc. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | ||
| ORAGENICS | 0,940 | +1,63 % | Oragenics Q2 2025 Shareholder Update | Advancing Brain-First Recovery Platform Toward Clinical MilestonesPioneering Intranasal Therapeutics for Concussion SARASOTA, Fla., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American:... ► Artikel lesen | |
| LADRX | - | - | LadRx Corp - 8-K, Current Report | ||
| UNITY BIOTECHNOLOGY | 0,030 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM XETRA - 10.10.2025 | The following instruments on XETRA do have their last trading day on 10.10.2025Die folgenden Instrumente in XETRA haben ihren letzten Handelstag am 10.10.2025ISIN NameDE000DB9U2Y9 DT.BANK IS. 20/25US44891CBN20... ► Artikel lesen | |
| TENAX THERAPEUTICS | 2,770 | -100,00 % | Tenax Therapeutics, Inc.: Tenax Therapeutics Announces European Patent Office Intention to Grant Patent Covering Use of Levosimendan in PH-HFpEF | Provides Patent Protection in Europe Through at Least December 2040 Further IP Protection for TNX-103 (Oral Levosimendan) and Other Drug Formulations, and its Active Metabolites, in PH-HFpEF Also... ► Artikel lesen | |
| SERES THERAPEUTICS | 14,640 | -0,54 % | Seres Therapeutics, Inc.: Seres Therapeutics Receives Award of Up to $3.6 Million from CARB-X to Develop Liquid Formulation of SER-155 | CAMBRIDGE, Mass., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that CARB-X (Combating Antibiotic-Resistant Bacteria... ► Artikel lesen |
Das Unternehmen POLYRIZON LTD kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -15,06 % bei einem Aktienkurs von 0,578 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu POLYRIZON LTD finden Sie auf Wallstreet Online.